The importance of Alexion to the future prospects for AstraZeneca PLC has been underlined by its strong contribution to Q1 sales and plans to set up a new US strategic R&D hub in Cambridge, MA that will also serve as the new corporate headquarters for the rare disease unit.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?